Evaluation of the effect of dapagliflozin on cardiac repolarization: A thorough QT/QTc study

Diabetes Therapy

Volumn 2, Issue 3, 2011, Pages 123-132

  Carlson, Glenn F ^a   Tou, Conrad K P ^a   Parikh, Shamik ^a   Birmingham, Bruce K ^a   Butler, Kathleen ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

dapagliflozin; QT interval; SGLT2 inhibitor; thorough QT study; type 2 diabetes mellitus

Indexed keywords

DAPAGLIFLOZIN; MOXIFLOXACIN; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONJUNCTIVITIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG FATALITY; DRUG HALF LIFE; ELECTROCARDIOGRAPHY MONITORING; HEADACHE; HEART PALPITATION; HEART RATE; HEART REPOLARIZATION; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; MALE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NAUSEA; NORMAL HUMAN; PARESTHESIA; PLASMA CONCENTRATION-TIME CURVE; PR INTERVAL; PRIORITY JOURNAL; PRURITUS; QRS COMPLEX; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RR INTERVAL; SIDE EFFECT; SINGLE DRUG DOSE; SORE THROAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TINEA VERSICOLOR; URTICARIA;

EID: 80052805929     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-011-0003-2     Document Type: Article

References (19)

1. International Diabetes Federation diabetes atlas. International Diabetes Federation. Available at: http://www. diabetesatlas. org/. Accessed February 16, 2010.
2. US Food and Drug Administration, Department of Health and Human Services. International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Federal Register. 2005; 70: 61134-61135.
3. Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008; 57: 1723-1729.
4. Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodiumdependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem. 2008; 51: 1145-1149.
5. Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009; 85: 520-526.
6. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009; 85: 513-519.
7. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009; 32: 650-657.
8. Wilding JPH, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers. Applicability of a novel insulin-independent treatment. Diabetes Care. 2009; 32: 1656-1662.
9. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010; 375: 2223-2233.
10. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Care. 2010; 33: 2217-2224.
11. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2005; 294: 2581-2586.
12. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356: 2457-2471.
13. Dota C, Skallefell B, Edvardsson N, Fager G. Computer-based analysis of dynamic QT changes: toward high precision and individual rate correction. Ann Noninvasive Electrocardiol. 2002; 7: 289-301.
14. Butler K, Wei C, Teng R. Single-dose ticagrelor does not prolong the QT interval in healthy subjects. Int J Clin Pharmacol Ther. 2010; 48: 643-651.
15. Garnett CE, Beasley N, Bhattaram VA, et al. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol. 2008; 48: 13-18.
16. Malik M, Garnett CE, Zhang J. Thorough QT studies: questions and quandaries. Drug Saf. 2010; 33: 1-14.
17. European Medicines Agency. ICH Topic E 14. The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Step 5. Questions and Answers. European Medicines Agency. Available at: www. emea. europa. eu/pdfs/human/ich/31013308en. pdf. Accessed October 12, 2008.
18. Bloomfield DM, Kost JT, Ghosh K, et al. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther. 2008; 84: 475-480.
19. International Conference on Harmonization of Technical requirements for registration of Pharmaceuticals for Hymna Use. The Clinical Evaluiation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs E-14. Available at: http://www. ich. org/products/guidelines/efficacy/article/efficacyguidelines. Accessed June 3, 2011.